Abstract
Aim: We investigated the association between RICTOR polymorphisms and clinical outcomes of platinum-based chemotherapy for Chinese non-small-cell lung cancer patients. Materials & methods: Ten tag SNPs were genotyped in 1004 patients to assess their association with clinical benefit, overall survival, progression-free survival, gastrointestinal toxicity, neutropenia, anemia and thrombocytopenia. Results: rs6878291 was significantly associated with clinical benefit (odds ratio: 2.037; p = 0.001) and reduced progression-free survival (hazard ratio: 1.461; p = 0.001). Stratified analysis showed that their most significant interaction was in nonsmokers. No association was observed between SNPs and other clinical outcomes. Conclusion: The study showed evidences for RICTOR polymorphisms’ role in platinum-based chemotherapy efficiency, which could provide new insight to lung cancer management.
To view the supplementary data that accompany this paper,please visit the journal website at:www.futuremedicine.com/doi/full/10.2217/pgs-2016-0070
Financial & competing interests disclosure
This work was supported by National Natural Science Foundation of China (no. 81372235, no. 31571371), the National High Technology Research and Development Program (“863” Program) of China (no. 2012AA02A518). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.